ICBP – Still Attractive Despite Higher Financing Costs
Despite higher interest expenses assumption, we expect ICBP to deliver strong earnings CAGR of 15.9% over FY19-22E with
Despite higher interest expenses assumption, we expect ICBP to deliver strong earnings CAGR of 15.9% over FY19-22E with
ERAA closed 1Q21 with an exceptional performance, maintaining the company’s momentum from last year. The double-digit
Going into 2021, we still prefer SIDO simply because it has a better margin among its peers, a healthy balance sheet,
Although MYOR successfully posted strong revenue growth in 1Q21, higher raw material cost caused earnings to contract.
KLBF reported 1Q21 results in line with market expectation. Meanwhile, we view KLBF is still attractive for a long-term
The company faced a multitude of challenges in 2020 from Indonesia’s large-scale social restriction and curfew. However,
We believe strong noodle and agribusiness sales will boost up INDF’s sales outlook. Meanwhile, we saw the overall margin
While we predict rising raw material price and weakening IDR will still continue this year, strong sales contribution
SIDO is our top pick in the healthcare sector given its resilience performance amid the unfavorable economic condition,